Nature Communications (Aug 2021)
Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern
- Donal T. Skelly,
- Adam C. Harding,
- Javier Gilbert-Jaramillo,
- Michael L. Knight,
- Stephanie Longet,
- Anthony Brown,
- Sandra Adele,
- Emily Adland,
- Helen Brown,
- Medawar Laboratory Team,
- Tom Tipton,
- Lizzie Stafford,
- Alexander J. Mentzer,
- Síle A. Johnson,
- Ali Amini,
- OPTIC (Oxford Protective T cell Immunology for COVID-19) Clinical Group,
- Tiong Kit Tan,
- Lisa Schimanski,
- Kuan-Ying A. Huang,
- Pramila Rijal,
- PITCH (Protective Immunity T cells in Health Care Worker) Study Group,
- C-MORE/PHOSP-C Group,
- John Frater,
- Philip Goulder,
- Christopher P. Conlon,
- Katie Jeffery,
- Christina Dold,
- Andrew J. Pollard,
- Alex Sigal,
- Tulio de Oliveira,
- Alain R. Townsend,
- Paul Klenerman,
- Susanna J. Dunachie,
- Eleanor Barnes,
- Miles W. Carroll,
- William S. James
Affiliations
- Donal T. Skelly
- Peter Medawar Building for Pathogen Research, Nuffield Department of Medicine, University of Oxford
- Adam C. Harding
- James and Lillian Martin Centre, Sir William Dunn School of Pathology, University of Oxford
- Javier Gilbert-Jaramillo
- James and Lillian Martin Centre, Sir William Dunn School of Pathology, University of Oxford
- Michael L. Knight
- James and Lillian Martin Centre, Sir William Dunn School of Pathology, University of Oxford
- Stephanie Longet
- Public Health England
- Anthony Brown
- Peter Medawar Building for Pathogen Research, Nuffield Department of Medicine, University of Oxford
- Sandra Adele
- Peter Medawar Building for Pathogen Research, Nuffield Department of Medicine, University of Oxford
- Emily Adland
- Peter Medawar Building for Pathogen Research, Department of Paediatrics, University of Oxford
- Helen Brown
- Peter Medawar Building for Pathogen Research, Nuffield Department of Medicine, University of Oxford
- Medawar Laboratory Team
- Tom Tipton
- Public Health England
- Lizzie Stafford
- Nuffield Department of Medicine, University of Oxford
- Alexander J. Mentzer
- Wellcome Centre for Human Genetics, University of Oxford
- Síle A. Johnson
- Oxford University Hospitals NHS Foundation Trust
- Ali Amini
- Peter Medawar Building for Pathogen Research, Nuffield Department of Medicine, University of Oxford
- OPTIC (Oxford Protective T cell Immunology for COVID-19) Clinical Group
- Tiong Kit Tan
- MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford
- Lisa Schimanski
- MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford
- Kuan-Ying A. Huang
- Department of Infectious Diseases, Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan, and Taipei Medical University
- Pramila Rijal
- MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford
- PITCH (Protective Immunity T cells in Health Care Worker) Study Group
- C-MORE/PHOSP-C Group
- John Frater
- Peter Medawar Building for Pathogen Research, Nuffield Department of Medicine, University of Oxford
- Philip Goulder
- Peter Medawar Building for Pathogen Research, Department of Paediatrics, University of Oxford
- Christopher P. Conlon
- Nuffield Department of Medicine, University of Oxford
- Katie Jeffery
- Oxford University Hospitals NHS Foundation Trust
- Christina Dold
- Oxford Vaccine Group, Department of Paediatrics, University of Oxford
- Andrew J. Pollard
- Oxford Vaccine Group, Department of Paediatrics, University of Oxford
- Alex Sigal
- Africa Health Research Institute
- Tulio de Oliveira
- School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal
- Alain R. Townsend
- MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford
- Paul Klenerman
- Peter Medawar Building for Pathogen Research, Nuffield Department of Medicine, University of Oxford
- Susanna J. Dunachie
- Peter Medawar Building for Pathogen Research, Nuffield Department of Medicine, University of Oxford
- Eleanor Barnes
- Peter Medawar Building for Pathogen Research, Nuffield Department of Medicine, University of Oxford
- Miles W. Carroll
- Public Health England
- William S. James
- James and Lillian Martin Centre, Sir William Dunn School of Pathology, University of Oxford
- DOI
- https://doi.org/10.1038/s41467-021-25167-5
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 12
Abstract
Understanding the effect of vaccination on emerging SARS-CoV-2 variants of concern is of increasing importance. Here, James et al. report that two doses of vaccination with the Pfizer-BioNTech vaccine induce more robust immune responses to the B.1.1.7 and B.1.351 SARS-CoV-2 lineages than does natural infection.
